Ototoxicity in children receiving cisplatin chemotherapy
- Authors
- Jang, H.J.; Cho, H.R.; Lee, J.H.; Bae, K.Y.; Seo, J.J.; Moon, H.N.; Im, H.J.
- Issue Date
- 2010
- Publisher
- Korean Pediatric Society
- Keywords
- Adolescent; Adverse effects; Children; Cisplatin; Hearing loss
- Citation
- Korean Journal of Pediatrics, v.53, no.2, pp 210 - 214
- Pages
- 5
- Journal Title
- Korean Journal of Pediatrics
- Volume
- 53
- Number
- 2
- Start Page
- 210
- End Page
- 214
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/46885
- DOI
- 10.3345/kjp.2010.53.2.210
- ISSN
- 1738-1061
2092-7258
- Abstract
- Purpose: Cisplatin is highly effective for the treatment of solid tumors in children. However, the clinical use of cisplatin is limited by its ototoxicity. The aim of this study was to evaluate the ototoxicity in children treated with cisplatin. Method: We performed a single institution retrospective analysis of pediatric oncology patients who received cisplatin therapy between January 2001 and January 2008. Thirty-seven patients with sufficient medical and audiologic data were included in this study. Results: The median age at the time of diagnosis was 10.7 (range 3.8-16.7) years. There were 16 males and 21 females. The underlying diseases were osteosarcoma (15 cases), medulloblastoma (14 cases), germ cell tumors (7 cases), and hepatoblastoma (1 case). The median individual dose was 100 mg/m2/cycle (56-200). The median cumulative dose was 480 mg/m2 (200-1,490). Sixteen patients (43%) received cranial radiotherapy. Of the 37 patients, 17 developed hearing loss, leading to an overall incidence of 46%. Logistic regression showed that age at treatment (P =0.04) and cumulative dose of cisplatin (P =0.005) were the significant risk factors in predicting hearing loss in children treated with cisplatin. In all the patients who had hearing loss, there was neither improvement nor aggravation during the follow-up (3-68 months). Conclusion: The cumulative dose of cisplatin (>500 mg/m2) and younger age at treatment (<12 years) were 2 most important risk factors for ototoxicity in patients treated with cisplatin. Serial audiometric evaluations are needed in the patients with risk factors during and after cisplatin treatment.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > College of Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/46885)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.